# PRODUCT INFORMATION

## CAY10717

*Item No. 19955*

**CAS Registry No.:** 1240322-54-6
**Formal Name:** 5-[[[2-methyl-5-[[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)benzoyl]amino]phenyl]methyl]amino]-1H-pyrrolo[2,3-b]pyridine-2-carboxylic acid, methyl ester
**MF:** $C_{29}H_{25}F_3N_6O_3$
**FW:** 562.5
**Purity:** ≥95%
**UV/Vis.:** $\lambda_{max}$: 234, 299, 378 nm
**Supplied as:** A crystalline solid
**Storage:** -20°C
**Stability:** ≥2 years



*Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.*

### Laboratory Procedures

CAY10717 is supplied as a crystalline solid. A stock solution may be made by dissolving the CAY10717 in the solvent of choice. CAY10717 is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide (DMF), which should be purged with an inert gas. The solubility of CAY10717 in these solvents is approximately 0.5, 12.5, and 30 mg/ml, respectively.

CAY10717 is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, CAY10717 should first be dissolved in DMF and then diluted with the aqueous buffer of choice. CAY10717 has a solubility of approximately 0.33 mg/ml in a 1:2 solution of DMF:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day.

### Description

CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM.[1] It has activity at multiple oncogenic kinases, with $IC_{50}$ values less than 50 nM against wild-type EGFR and ABL and mutant $ABL^{G250E}$, $ABL^{Y253F}$, $ABL^{E255K}$, and B-$Raf^{V600E}$. CAY10717 is highly cytotoxic against a cancer cell panel that includes chemotherapy-sensitive and -resistant cell lines ($EC_{50}$s = 0.4-158 nM). It also inhibits the growth of human umbilical vein endothelial cells (HUVECs; $EC_{50}$ = 34 nM), a model for tumor angiogenesis.

### Reference


1. Daydé-Cazals, B., Fauvel, B., Singer, M., *et al.* Rational design, synthesis, and biological evaluation of 7-azaindole derivatives as potent focused multi-targeted kinase inhibitors. *J. Med. Chem.* **59(8)**, 3886-3905 (2016).



**WARNING**
THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

**SAFETY DATA**
This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent *via* email to your institution.

**WARRANTY AND LIMITATION OF REMEDY**
Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 09/07/2017



**CAYMAN CHEMICAL**
1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA
**PHONE:** [800] 364-9897
[734] 971-3335
**FAX:** [734] 971-3640
CUSTSERV@CAYMANCHEM.COM
WWW.**CAYMANCHEM**.COM